藥物質譜市場規模、佔有率和成長分析：按技術採用、業務應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球藥物質譜市場價值為 14.3 億美元，預計到 2025 年將成長至 15.7 億美元，到 2033 年將成長至 32.9 億美元，在預測期（2026-2033 年）內複合年成長率為 9.7%。

由於質譜技術在藥物生命週期的各個階段對藥物化合物的鑑定、定量和解析發揮至關重要的作用，全球藥物質譜市場正經歷顯著成長。藥物研發中對效率和安全性的日益成長的需求，使得高解析度質譜成為一項監管要求的技術。從傳統的單四極桿分析器轉向先進的液相層析串聯質譜（LC-MS/MS）和Orbitrap系統的轉變，凸顯了提升分析能力的創新。監管要求，特別是生物相似藥方面的要求，正促使實驗室快速採用這些技術。此外，生物製藥和標靶治療的興起，使得高靈敏度分析變得至關重要，從而推動了對尖端設備的投資。個人化醫療和人工智慧驅動的自動化技術的出現，進一步提升了處理能力和準確性，鞏固了藥物研發和品管領域向數據驅動和高效實踐轉變的市場趨勢。

全球藥物質譜市場促進因素

全球藥物質譜市場的主要驅動力在於尖端技術卓越的分析靈敏度，這些技術能夠檢測微量生物分子。這種能力在疾病的早期診斷和個人化治療方案的開發中發揮著至關重要的作用，從而帶動了對能夠提供高解析度數據的質譜平台的需求成長。製藥公司正擴大採用先進的分析儀器，這不僅提高了研究結果的可靠性，也簡化了藥物研發流程。此外，性能的持續提升促進了生物技術領域的合作，並鼓勵企業投資於最尖端科技。因此，持續的產品創新和不斷拓展的應用前景正在推動市場成長。

全球藥物質譜市場限制因素

全球醫藥質譜市場面臨巨大的挑戰，因為其所需的巨額資本投入對許多製藥公司，尤其是中小企業和學術機構而言，構成了一道難以克服的障礙。引進、安裝和維護先進質譜系統的高昂初始成本阻礙了這些機構採用此類技術，從而限制了市場的成長和擴張。資金限制迫使這些機構將重點放在必要的設備上，往往導致升級到最新技術的進程被延誤甚至完全擱置。因此，這些資金壁壘限制了部分潛在用戶獲得先進的、資本密集解決方案的機會。

全球藥物質譜市場趨勢

全球藥物質譜市場正經歷著向自動化和人工智慧驅動的工作流程的顯著轉變。製造商正日益將機器人樣品處理和即時數據處理功能與先進的人工智慧演算法相結合，以預測最佳採集參數。這種數位化最大限度地減少了人工干預，加快了分析週期，並提高了實驗室間的可重複性。此外，隨著供應商提供包含機器學習模型的承包解決方案，用於峰值識別和定量評估，製藥公司可以有效地擴展其高通量篩檢工作。這種轉變不僅簡化了研發流程和成本結構，也加快了整個藥物發現流程的決策速度，從而增強了該領域的全球競爭力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球藥物質譜市場規模：依技術採用模式分類

• 單四極系統
  • 液界面
  • 氣體界面
• 四極系統
• 高解析度混合質譜

全球藥物質譜市場規模：依應用領域分類。

• 生物製藥的結構分析
• 雜質鑑定與分析
• 生物分析方法的驗證測試
• 藥品品管和製程監控

全球藥物質譜市場規模：依最終用戶分類

• 商業製藥廠商
• 生物製藥契約製造
• 監管測試機構

全球藥物質譜市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific
• Danaher Corporation
• Agilent Technologies
• Waters Corporation
• Bruker Corporation
• Shimadzu Corporation
• PerkinElmer
• Jeol Ltd
• Hitachi
• Tosoh Corporation
• Bio-Rad Laboratories
• Merck KGaA
• Qiagen
• F. Hoffmann-La Roche
• Abbott Laboratories
• Becton Dickinson
• Sysmex Corporation
• Horiba
• Rigaku Corporation
• Oxford Instruments

結論與建議

Global Pharma Mass Spectrometry Market size was valued at USD 1.43 Billion in 2024 and is poised to grow from USD 1.57 Billion in 2025 to USD 3.29 Billion by 2033, growing at a CAGR of 9.7% during the forecast period (2026-2033).

The global pharma mass spectrometry market is experiencing significant growth due to its essential role in identifying, quantifying, and elucidating drug compounds during various stages of the pharmaceutical lifecycle. The increasing need for efficiency and safety in drug development has solidified high-resolution mass spectrometry as a regulatory staple. The transition from traditional single-quadrupole analyzers to advanced LC-MS/MS and Orbitrap systems highlights innovations that enhance analytical capabilities. Regulatory demands, particularly around biosimilars, are driving labs to adopt these technologies swiftly. Additionally, the rise of biologics and targeted therapies necessitates sensitive analyses, prompting investments in cutting-edge equipment. The emergence of personalized medicine and AI-driven automation further amplifies throughput and accuracy, solidifying the market's trajectory toward more data-centric and efficient practices in pharmaceutical research and quality control.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharma Mass Spectrometry market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharma Mass Spectrometry Market Segments Analysis

Global pharma mass spectrometry market is segmented by technology implementation, operational application, end-user and region. Based on technology implementation, the market is segmented into Single Quadrupole Systems, Triple Quadrupole Systems and High-Resolution Hybrid Mass Spectrometry. Based on operational application, the market is segmented into Biopharmaceutical Structural Characterization, Impurity Identification Profiling, Bioanalytical Method Validation Testing and Formulations Quality Control Process Monitoring. Based on end-user, the market is segmented into Commercial Pharmaceutical Producers, Biologics Contract Manufacturers and Regulatory Testing Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharma Mass Spectrometry Market

The Global Pharma Mass Spectrometry market is significantly driven by the advanced analytical sensitivity of modern technologies, which allows for the detection of trace biomolecules. This capability plays a crucial role in early disease diagnosis and the development of personalized therapies, leading to a heightened demand for mass spectrometry platforms offering high-resolution data. Pharmaceutical companies are increasingly adopting sophisticated instruments, which boosts confidence in research findings and streamlines drug discovery processes. Furthermore, this ongoing enhancement of performance encourages collaboration among biotechnological sectors, prompting firms to invest in state-of-the-art technologies, thereby facilitating market growth through continuous product innovation and expanded application possibilities.

Restraints in the Global Pharma Mass Spectrometry Market

The Global Pharma Mass Spectrometry market faces significant challenges due to high capital investment requirements that hinder many pharmaceutical companies, especially smaller entities and academic institutions. The considerable initial expenses involved in acquiring, installing, and maintaining sophisticated mass spectrometry systems can dissuade these organizations from embracing such technologies, which in turn restricts market growth and expansion. Financial limitations force entities to focus on essential equipment, often leading to delays or complete omissions in upgrading to the latest innovations. As a result, the presence of these financial barriers limits access to advanced, capital-intensive solutions for a portion of potential users within the market.

Market Trends of the Global Pharma Mass Spectrometry Market

The Global Pharma Mass Spectrometry market is witnessing a significant trend towards automation and AI-driven workflows. Manufacturers are increasingly integrating robotic sample handling and real-time data processing capabilities with advanced artificial intelligence algorithms, which predict optimal acquisition parameters. This digitization minimizes manual intervention and accelerates analysis cycles, offering enhanced reproducibility across laboratories. Furthermore, as vendors provide turnkey solutions that incorporate machine learning models for peak identification and quantitative assessment, pharmaceutical companies can effectively scale high-throughput screening initiatives. This transformation not only streamlines R&D timelines and cost structures but also enhances decision-making speed throughout discovery pipelines, driving global competitiveness in the sector.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pharma Mass Spectrometry Market Size by Technology Implementation & CAGR (2026-2033)

• Market Overview
• Single Quadrupole Systems
  • Liquid Interface
  • Gas Interface
• Triple Quadrupole Systems
• High-Resolution Hybrid Mass Spectrometry

Global Pharma Mass Spectrometry Market Size by Operational Application & CAGR (2026-2033)

• Market Overview
• Biopharmaceutical Structural Characterization
• Impurity Identification Profiling
• Bioanalytical Method Validation Testing
• Formulations Quality Control Process Monitoring

Global Pharma Mass Spectrometry Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Commercial Pharmaceutical Producers
• Biologics Contract Manufacturers
• Regulatory Testing Laboratories

Global Pharma Mass Spectrometry Market Size & CAGR (2026-2033)

• North America (Technology Implementation, Operational Application, End-User)
  • US
  • Canada
• Europe (Technology Implementation, Operational Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology Implementation, Operational Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology Implementation, Operational Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology Implementation, Operational Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jeol Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tosoh Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horiba
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rigaku Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Instruments
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations